Progressive Pulmonary Fibrotic Lung Disease (PPF)

We have launched several treatments for a range of respiratory conditions in areas of high unmet patient need, including asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). Our recent breakthrough treatment for generalized pustular psoriasis begins a new tradition of innovation excellence in immunology.

Scientists in our global network of research centers are connecting with partners across the scientific community to advance the search for novel therapeutic concepts, biomarkers, drug candidates and treatment modalities that address unmet need and offer patients and doctors improved options with high efficacy, few side effects and convenient dosage forms and regimens.

We are further strengthening our existing portfolio in immunology and respiratory diseases through external collaborations, with a focus on pre-clinical assets and opportunistic early clinical licensing.

• Targets and biomarkers in anti-fibrotic and anti-inflammatory diseases
• New therapeutic concepts addressing innate and adaptive immunity, vascular biology and epithelial barrier dysfunction
• Therapeutics for rare dermatological disorders